Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07097870
Starting soon Observational

Predictors of HCC in Post-HCV Cirrhotic Patients After SVR

NCT07097870 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sohag University
Phase
Observational
Started
2025-08
Last updated
2025-08-05

Condition(s) studied

HCC - Hepatocellular Carcinoma

Study summary

This study aims to identify clinical and laboratory factors that predict the occurrence of hepatocellular carcinoma (HCC) in Egyptian cirrhotic patients after achieving a sustained virologic response (SVR) to hepatitis C virus (HCV) treatment. This is a retrospective, two-center, case-control study that will include 132 cases and 264 controls. Variables to be analyzed include demographics, liver disease status, metabolic comorbidities, lifestyle factors, medications, as well as laboratory parameters and non-invasive scoring systems.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * for cases: 1. age ≥ 18 y; 2. HCV related cirrhosis; 3. SVR12 after DAA; 4. radiologic or histologic HCC diagnosis ≤30 Jun 2025 * for controls: As above plus, ≥36 months post SVR without HCC Exclusion Criteria: * for cases: 1. non HCV cirrhosis or combined HCV-HBV cirrhosis; 2. HCC \<6 months before SVR; 3. concomitant cholangiocarcinoma * for controls: Same as cases, plus, loss to follow up before 36 months

Primary outcome measure(s)

  • occurrence of hepatocellular carcinoma (HCC) — from SVR12 achievement to 6-9 years later (time of data collection)
    measure occurrence of HCC in post-HCV liver cirrhosis after achieving SVR, by comparing cases to controls

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine, Sohag Univesity Sohag Egypt

More Sohag University trials in Egypt

The Effect of an Integrated Mobile Health Platform on Early Detection of Clinical Outcomes of Critical Ill Patients Starting soon
Short-term Outcomes of High Tibial Osteotomy Using a Plate Versus a Plate With an Interbody Fusion Cage in Adolescent Tibia Vara : a Comparative Study Active, not recruiting
The Accuracy Of 3D Color Ultrasonography for Detecting the Degree of Placenta Accreta Spectrum Invasion Enrolling by invitation
Assessment of Risk Factors for Incisional Hernia Following Major Abdominal Surgery Recruiting
Serum Albumin in Acute Coronary Syndrome Starting soon

Other trials for the same condition

Real-world Insight Into Systemic Therapies for HCC: Single-center Study Recruiting
Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals Enrolling by invitation
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07097870 on ClinicalTrials.gov ↗ ← All trials in Egypt